LOS ANGELES, Feb. 5, 2018 /PRNewswire/ -- CytRx
Corporation (NASDAQ: CYTR), a biopharmaceutical research and
development company specializing in oncology, today
highlighted that aldoxorubicin licensee NantCell, Inc., a
private subsidiary of NantWorks, LLC, has dosed the first patient
in the Phase 1b portion of a Phase
1b/2 clinical trial for patients with
advanced squamous cell carcinoma (SCC) of either the head and neck
or non-small cell lung cancer. This is the second trial
conducted by NantCell which will investigate high-affinity natural
killer (haNK) cell therapy in combination with anti-cancer agents,
including aldoxorubicin, in certain high unmet need cancer
indications. The first trial in pancreatic cancer patients
commenced in January 2018.
"This is the second clinical trial initiated this year by
NantCell to include aldoxorubicin, and we are extremely pleased
with their clinical progress to date," said Steven A. Kriegsman, CytRx's Chairman and
CEO. "We look forward to further positive developments as
NantCell continues to advance aldoxorubicin in combination with
immuno-oncology agents and cell-based therapies. In parallel,
the CytRx team is focused on advancing our novel LADR™ drug
candidates where we remain on track to nominate one or more new
candidates for clinical development by the end of this
quarter."
The trial titled "QUILT-3.090: Molecularly Informed
Integrated Immunotherapy in Subjects With SCC Who Have Progressed
on or After Platinum-based Chemotherapy and Anti-programmed Cell
Death Protein 1 (PD-1)/Programed Death Ligand 1 (PD-L1)
Therapy," (NCT03387111) is a single-center, open-label, Phase
1b/2 clinical trial designed to
evaluate the safety and efficacy of several combination therapies,
including combinations with aldoxorubicin, in subjects with SCC who
have progressed on or after platinum-based chemotherapy and
anti-PD1/PD-L1 therapy. This trial is expected to enroll
approximately 65 patients. The primary endpoint for the Phase
1b portion of the trial is safety and
the primary endpoint for the Phase 2 portion of the trial is
objective response rate (ORR) by RECIST.
About CytRx Corporation
CytRx Corporation is a biopharmaceutical company specializing in
research and clinical development of novel anti-cancer drug
candidates that employ linker technologies to enhance the
accumulation and release of drug at the tumor. CytRx is also
rapidly expanding its pipeline of ultra-high potency oncology
candidates at its laboratory facilities in Freiburg, Germany, through its LADR™ (Linker Activated
Drug Release) technology platform, a discovery engine designed to
leverage CytRx's expertise in albumin biology and linker technology
for the development of a new class of potential breakthrough
anti-cancer therapies. Aldoxorubicin, CytRx's most advanced
drug conjugate, is an improved version of the widely used
anti-cancer drug doxorubicin and has been out-licensed to NantCell,
Inc.
Forward-Looking Statements
This press release contains forward-looking statements. Such
statements involve risks and uncertainties that could cause actual
events or results to differ materially from the events or results
described in the forward-looking statements, including risks and
uncertainties relating to plans for regaining compliance with the
Nasdaq rules and higher share price of our common stock; the
ability of NantCell, Inc., to obtain regulatory approval for its
products that use aldoxorubicin; the ability of NantCell, Inc., to
manufacture and commercialize products or therapies that use
aldoxorubicin; the amount, if any, of future milestone and royalty
payments that we may receive from NantCell, Inc.; our ability to
develop new ultra-high potency drug candidates based on our LADRTM
technology platform; and other risks and uncertainties described in
the most recent annual and quarterly reports filed by CytRx with
the Securities and Exchange Commission and current reports filed
since the date of CytRx's most recent annual report. All
forward-looking statements are based upon information available to
CytRx on the date the statements are first published. CytRx
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Investor Relations Contact:
Argot Partners
Michelle Carroll
(212) 600-1902
michelle@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/cytrx-corporation-highlights-second-nantcell-inc-clinical-trial-evaluating-immuno-oncology-agents-and-cell-based-therapies-in-combination-with-aldoxorubicin-in-patients-with-advanced-squamous-cell-carcinoma-300593210.html
SOURCE CytRx Corporation